Sign In
Buy VRTX
$428.34
+3.25 (+0.765%)
At Close: Jun 03, 2026
VRTX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Vertex Pharmaceuticals Incorporated investment
07:25am, Tuesday, 11'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDA
Vertex Pharmaceuticals Incorporated (VRTX) Q4 2024 Earnings Call Transcript
08:26pm, Monday, 10'th Feb 2025
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Q4 2024 Earnings Conference Call February 10, 2025 4:30 PM ET Company Participants Susie Lisa - Senior Vice President, Investor Relations Reshma Kewa
Markets Steady, Positive; Q4 Earnings Keep Rolling
07:11pm, Monday, 10'th Feb 2025
Indexes mostly shrugged off +25% steel tariffs announced by President Trump; VRTX, LSCC report for Q4.
Vertex Pharmaceuticals (VRTX) Misses Q4 Earnings Estimates
06:11pm, Monday, 10'th Feb 2025
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $3.98 per share, missing the Zacks Consensus Estimate of $3.99 per share. This compares to earnings of $4.20 per share a year ago.
Vertex's Revenue Surges but EPS Slips
05:56pm, Monday, 10'th Feb 2025
Vertex Pharmaceuticals (VRTX 0.14%), known for its innovative treatments, reported its fourth-quarter earnings on Feb. 10. The company's revenue increased significantly to $2.91 billion, which was abo
Vertex Pharmaceuticals' Revenue Forecast Tops Expectations
04:40pm, Monday, 10'th Feb 2025
Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts' expectations.
Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand
04:14pm, Monday, 10'th Feb 2025
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its cystic fibrosis drugs and early contributions from a newly approved non-opi
Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
04:01pm, Monday, 10'th Feb 2025
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided its
Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?
02:46pm, Monday, 10'th Feb 2025
We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.
VRTX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Vertex Pharmaceuticals Incorporated investment
07:30am, Monday, 10'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDA
Top Wall Street Forecasters Revamp Vertex Pharmaceuticals Price Expectations Ahead Of Q4 Earnings
07:24am, Monday, 10'th Feb 2025
Vertex Pharmaceuticals Incorporated VRTX will release its fourth-quarter financial results, after the closing bell, on Monday, Feb. 10, 2025.
2 Biotech Stocks to Buy Hand Over Fist in February
11:15am, Sunday, 09'th Feb 2025
Equity markets performed well in January, as they often do, but as the dust settles on that early-year run, the strategy for long-term investors remains the same: Invest in companies that can perform
NEW YORK, NY / ACCESS Newswire / February 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ
Final Trades: Energy Transfer, Vertex Pharma, UnitedHealth and Axon Enterprise
01:30pm, Wednesday, 05'th Feb 2025
The Investment Committee give you their top stocks to watch for the second half.
